PF-Atlas › Clinical Trials › NCT02273661
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis .
Liposomal amphotericin B · Phase 2
Registry ID
NCT02273661
Phase
Phase 2
Status
Completed
Drug / intervention
Liposomal amphotericin B (Ambisome®)
Sponsor
Poitiers University Hospital
Start
2014-11-19
About this trial
Liposomal amphotericin B is evaluated in NCT02273661, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Poitiers University Hospital. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02273661 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.